Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Notices 11251 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Fax: 202–395–7285, 

E-mail: 

OIRA_SUBMISSION@OMB.EOP.GOV, 

Attn: Desk Officer for the 

Administration for Children and 

Families. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2011–4418 Filed 2–28–11; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0099] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Followup Study for 

Infant Feeding Practices Study II 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the Agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal Agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

a study entitled ‘‘Followup Study for 

Infant Feeding Practices Study II.’’ 

DATES: Submit either electronic or 

written comments on the collection of 

information by May 2, 2011. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to http:// 

www.regulations.gov. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Denver Presley, Office of Information 

Management, Food and Drug 

Administration, 1350 Piccard Dr., PI50– 

400B, Rockville, MD 20850, 301–796– 

3793. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

Agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined in 

44 U.S.C. 3502(3) and 5 CFR 1320.3(c) 

and includes Agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires Federal Agencies 

to provide a 60-day notice in the 

Federal Register concerning each 

proposed collection of information 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 

Followup Study for Infant Feeding 

Practices Study II (OMB Control 

Number 0910–NEW) 

I. Background 

FDA is planning to conduct a survey 

of the mothers who participated in the 

Infant Feeding Practices Study II (IFPS 

II) (Ref. 1). The IFPS II sample was 

drawn from a commercial consumer 

opinion panel, and so participants are 

expected to be easier to re-contact than 

would be the case for a random sample 

of the population. Some participants 

will still be panel members. The 

purpose of the study is to enhance 

FDA’s understanding of the associations 

between infant feeding practices and 

diet quality, food allergy, overweight 

and obesity, and other health and 

development outcomes in young 

children. 

The study results will be used to help 

the Agency to understand the possible 

role of infant feeding practices in the 

development and progression of food 

allergy and childhood overweight and 

obesity, in addition to resistance to 

infection and other health and 

development outcomes. The results of 

the study will not be used to develop 

population estimates. 

The data will be collected by a mailed 

questionnaire from most respondents 

and by telephone from those who do not 

respond to the mailed questionnaire. 

The study will focus on the following 

types of information: The child’s 

consumption of various food groups; the 

child’s other consumption practices 

(such as how often the child eats dinner 

with a parent and how often the child 

eats from fast food restaurants); the 

mother’s control over the child’s eating 

patterns; the child’s physical activity 

and time spent watching a screen (TV or 

computer); the child’s sleep patterns; 

extent of the child’s cognitive 

stimulation at home; the child’s height, 

weight, and waist circumference; the 

child’s visits to a dentist and number of 

cavities; number of the child’s recent 

physician visits; number of various 

types of infections the child had in the 

past year; whether the child has various 

health conditions including digestive 

problems, eczema, food allergy, 

respiratory allergy, attention deficit 

disorder, developmental delay, anxiety 

problems, depression, or asthma; the 

child’s social development; the child’s 

family medical history; the mother’s 

height and weight, physical activity, 

depression, pregnancies subsequent to 

the sample child and whether 

subsequent children were breastfed, and 

employment conditions; the mother or 

child’s participation in certain 

government programs; and the child’s 

potential exposure to certain 

environmental contaminants including 

cigarette smoke and pesticides. A 

demographic questionnaire will also be 

mailed to respondents for whom current 

information is not available through the 

consumer opinion panel. Participation 

in the study is voluntary. 

To refine the questionnaire used in 

the study, a pretest will be conducted 

with 100 participants, 91 by mailed 

questionnaire and 9 by telephone 

interview. We estimate that it will take 

a respondent 20 minutes (0.33 hours) to 

complete the survey and 5 minutes (0.08 

hours) to complete debriefing questions 

for the pretest, for a total of 25 minutes 

(0.42 hours) per respondent and a total 

of 38 hours for the mailed and 4 hours 

for the interview pretest. The sample for 

the pretest will be panel members who 

are mothers of children 5 to 7 years old 


jlentini on DSKJ8SOYB1PROD with NOTICES
11252 Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Notices 

who did not participate in the IFPS II. 

All IFPS II participants who completed 

at least two surveys after their infants 

were born and for whom current contact 

information can be found will be sent 

the mailed questionnaire. This is 

expected to be about 2,562 participants. 

We estimate that 1,538 respondents will 

return it and that it will take a 

respondent 20 minutes (0.33 hours) to 

complete the questionnaire, for a total of 

513 hours. An additional 522 mothers 

are expected to complete the telephone 

interview of 20 minutes (0.33 hours) for 

a total of 174 hours. An estimated 1,380 

participants will return the 

demographic questionnaire, which will 

require 5 minutes (0.08 hours) to 

complete for a total of 110 hours. Thus, 

the total estimated burden is 839 hours. 

FDA’s burden estimate is based on prior 

experience with consumer surveys that 

are similar to this proposed data 

collection. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

Portion of study No. of 

respondents 

Annual 

frequency 

per response 

Total annual 

responses 

Hours per 

response Total hours 

Pretest mailed questionnaire ............................................... 91 1 91 0.42 38 

Pretest telephone interview ................................................. 9 1 9 0.42 4 

Main study mailed questionnaire ......................................... 1,538 1 1,538 0.33 513 

Main study telephone interview ........................................... 522 1 522 0.33 174 

Demographic questionnaire ................................................. 1,380 1 1,380 0.08 110 

Total .............................................................................. ........................ ........................ ........................ ........................ 839 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

II. References 

The following reference has been 

placed on display in the Division of 

Dockets Management (see ADDRESSES) 

and may be seen by interested persons 

between 9 a.m. and 4 p.m., Monday 

through Friday. 

1. Fein, Sara B., Judith Labiner-Wolfe, 

Katherine Shealy, et al., ‘‘Infant Feeding 

Practices Study II: Study Methods,’’ 

Pediatrics 2008; 122(suppl 2): S28–S35. 

Dated: February 22, 2011. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2011–4459 Filed 2–28–11; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 USC, 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group; Training 

and Career Development Subcommittee. 

Date: March 9–10, 2011. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Eliane Lazar-Wesley, 

Ph.D., Health Scientist Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4245, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–451–4530, el6r@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA– 

K Conflicts. 

Date: March 9, 2011. 

Time: 5 p.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4238, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–402–6626, 

gml45a@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Pharmacological Development of Treatment 

Agents and Formulations or Tobacco 

Dependence. 

Date: March 18, 2011. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Jose F. Ruiz, Ph.D., 

Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, Room 4228, MSC 9550, 

6001 Executive Blvd., Bethesda, MD 20892– 

9550, (301) 451–3086, ruizjf@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; High 

Throughput Screening for Nicotinic Receptor 

Subunits. 

Date: March 24, 2011. 

Time: 2:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 4238, MSC 

9550, 6001 Executive Blvd., Bethesda, MD 

20892–9550, 301–402–6626, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Training in Computational Neuroscience 

(T90/R90). 

Date: March 30, 2011. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Minna Liang, Ph.D., 

Scientific Review Officer, Grants Review 

Branch, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, Room 

4226, MSC 9550, 6001 Executive Blvd., 


jlentini on DSKJ8SOYB1PROD with NOTICES